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Abstract
The cyclotide MCoTI-II is a powerful trypsin inhibitor recently isolated from the seeds of 
Momordica cochinchinensis, a plant member of cucurbitaceae family. We report for the first 
time the in vivo biosynthesis of natively-folded MCoTI-II inside live E. coli cells. Our 
biomimetic approach involves the intracellular backbone cyclization of a linear cylotide-intein 
fusion precursor mediated by a modified protein splicing domain. The cyclized peptide then 
spontaneously folds into its native conformation. The use of genetically engineered E. coli cells 
containing mutations in the glutathione and thioredoxin reductase genes considerably improves 
the production of folded MCoTI-II in vivo. Biolchemical and structural characterization of the 
recombinant MCoTI-II confirmed its identity. Biosynthetic access to correctly-folded cyclotides 
allows the possibility of generating cell-based combinatorial libraries that can be screened inside 
living cells for their ability to modulate or inhibit cellular processes.
Keywords: Cyclotides, trypsin inhibitor, backbone cyclization, protein splicing, protein 
engineering, cyclic protein. 
Cyclotides are a new emerging family of large plant-derived backbone-cyclized polypeptides 
(≈28-37 amino acids long) that share a disulfide-stabilized core (3 disulfide bonds) characterized 
by an unusual knotted structure (Figure 1) [1, 2]. In this motif, an embedded ring in the structure 
formed by two disulfide bonds and their connecting backbone segments is penetrated by the third 
disulfide bond. Cyclotides contrast with other circular poylpeptides in that they have a highly 
defined three-dimensional structure, and despite their small size, can be considered as 
miniproteins. Their unique circular backbone topology and knotted arrangement of 3 disulfide 
bonds makes them exceptionally stable to thermal and enzymatic degradation [3]. Furthermore, 
their well defined structures have been also associated with a range of biological activities, 
including uterotonic [4], neurotensin antagonistic [5], hemolytic [6, 7], anti-HIV [8], antibacterial [7], 
insecticidal [9] and trypsin inhibitory [10] activities. Together, these characteristics make 
cyclotides ideal candidates to be used as molecular scaffolds for the development of stable 
peptide drugs [11, 12]. 
Although the chemical synthesis of several cyclotides using solid-phase peptide synthesis have 
been reported [7, 13-15], having access to biosynthetic cyclotides using recombinant DNA
expression techniques offers the exciting possibility of producing large combinatorial libraries of 
highly stable miniproteins using the tools of molecular biology. This would allow the generation 
of cell-based libraries that could be screened either in vitro or in vivo for their ability to regulate 
cellular processes. 
In nature, cyclotides are ribosomally synthesized as precursor proteins that are then subsequently 
processed into the corresponding circular polypeptide [9, 16]. Despite knowledge of the underlying 
gene sequences of different cyclotides, the mechanism that governs circularization is not totally 
understood.  Although the possibility of an autocatalytic split-intein-type mechanism has not yet 
been disproved, it is more likely the involvement of specialized proteolytic enzymes. 
In an attempt to biosynthesize cyclotides inside living cells, our group recently reported the use 
of engineered protein splicing units for the in vitro cyclization and folding of cyclotides using 
conditions similar to those found inside living cells [17]. Our biomimetic approach is based on the 
use of an intramolecular version of native chemical ligation (NCL) [18] to produce the head-to-tail 
or backbone cyclization of the corresponding linear cyclotide precursor (Figure 2). 
Intramolecular NCL requires the presence of an N-terminal Cys residue and C-terminal a-
thioester group in the same linear precursor [19, 20]. As shown in Figure 2, this was accomplished 
by producing a recombinant protein where the linear cyclotide precursor was fused in frame at its 
C- and N-terminus to a modified intein and a Met residue, respectively. This allows the 
generation of the required C-terminal thioester function [21] and N-terminal Cys residue [22]. This 
approach was successfully used for the in vitro biosynthesis of different Kalata B1-based 
cyclotides [17]. 
In the present work we report the use of a similar approach for the in vivo biosynthesis of a fully 
folded and biologically active cyclotide inside living bacterial cells. For this purpose we used a 
modified gyrase intein [23] instead. This bacterial-derived mini-intein is considerably smaller 
(≈27 kDa) than the previously employed vacuolar membrane ATPase (VMA) intein[24] (≈57 
kDa) and shows high levels of expression in bacterial expression systems. This ensures a higher 
level of expression for the corresponding cyclotide linear precursor. Incorporation of Met residue 
at the N-terminus of the cyclotide linear precursor sequence makes possible the generation of a 
N-terminal Cys residue by endogeneous Met aminopeptidase (MAP) as the precursor intein 
fusion protein is translated in vivo [25]. Initial attempts to use the gyrase intein for the cyclization 
of the cyclotide KB1, however, were unsuccessful [17] due to difficulties associated with 
purification of the corresponding folded cyclotide from a complex soluble cellular fraction. 
Despite the fact that KB1 was the first cyclotide to be discovered and it has been structurally 
well characterized, its biological function is not well understood and no binding partners have 
yet been identified. This made impossible to use of any type of affinity chromatography for its 
purification from the cytosolic fraction. In order to facilitate purification and determine wheter 
folded cyclotides could be produced inside living cells, we decided to use the cyclotide MCoTI-
II (Momordica cochinchinensis trypsin inhibitor II, Figure 1) [10] instead. This cyclotide is a 
powerful trypsin inhibitor (Ki ≈ 30 pM) that has been recently isolated from a plant of the 
squash-family and it. Moreover, its three-dimensional structure has also been recently 
determined by NMR by two independent groups [26, 27] confirmimg its cyclic cystine knot (CCK) 
topology (Figure 1).
In vivo production of folded MCoTI-II was first explored by expressing several MCoTI-intein 
fusion proteins (1 through 3, Scheme 1) in Escherichia coli strain BL21(DE3).  Each construct 
was designed to use a different N-terminal Cys residue for the cyclization site. Hence, constructs 
1 and 2 used the naturally occurring Cys residues at the beginning and end of loop 6, 
respectively. This loop contains a highly flexible peptide sequence and it is not required for 
folding or biological activity [28]. In fact, this loop is missing in MCoTI-III (a related acyclic 
trypsin inhibitor from the same plant) and not found in related linear trypsin inhibitors from other 
plants of the squash-family [14]. Construct 3 used the native Cys residue at the end of loop 3. 
Fusion proteins 1 and 2 expressed at very high level in E. coli (≈40 mg/L). The expression level 
for construct 3, however, was significantly less (≈4 mg/L). Affinity purification of the fusion 
proteins revealed that all the constructs had similar levels of in vivo cleavage (≈60%, Figure 3a). 
Treatment of the purified fusion proteins with reduced glutathione for 2 days at pH 7.4 yielded 
the folded MCoTI-II as one of the major components obtained from constructs 1 and 3. 
Construct 2, however, gave a more complex crude reaction with only minor amounts of folded 
product when treated under the same conditions. This was attributed to the inefficient removal of 
the N-terminal Met residue by MAP. It has been described that the presence of Pro reside in 
position P2’ considerably reduces the proteolytic efficiency of MAP [29].
Next, we tried the isolation of the folded MCoTI-II generated in vivo after expression of 
construct 1 in E. coli BL21(DE3) cells. This was accomplished by incubating the soluble fraction 
of a fresh cell lysate with trypsin-immobilized agarose beads. After extensive washing, the 
absorbed products were eluted with a solution of 8 M GdmCl and analyzed by HPLC. As shown 
in Figure 3b, the analytical HPLC trace revealed the presence of a major component, which had 
the expected mass for the fully folded MCoTI-II (Figure 3b inset). A fresh cell sample was also 
lysated in the presence of 20 mM ICH2CONH2 and purified using trypsin-agarose beads as 
described above. The presence of ICH2CONH2 quenches any cyclization/folding that may take 
place during the lysis step. In both cases the amount of folded MCoTI-II found in the soluble 
cellular fraction was identical, indicating that the folded cyclotide was produced in vivo and not 
during the lysis step. The intracellular concentration of folded MCoTI-II was estimated ≈100 
nM. In vivo formation of folded MCoTI-II was further improved by expressing construct 1 in E. 
coli Origami 2(DE3) cells. These genetically engineered bacterial cells contain several mutations 
in the thioredoxin and glutathione reductases that favor the formation of disulfide bridges [30]. 
Hence, construct 1 was expressed very efficiently in Origami 2 cells, with expression levels 
similar to those obtained in BL21 cells. The expression level of folded MCoTI-II was estimated 
to be ≈33 µg/L of cell culture. Although the overall yield for the in vivo cyclization and folding 
process was rather small (≈2%), the intracellular concentration of MCoTI-II produced inside 
Origami cells was estimated ≈5 µM, which is high enough to carry out in vivo screening 
experiments [31, 32].
Biochemical and structural characterization confirmed the identity of the recombinantly 
produced MCoTI-II cyclotide. The trypsin inhibitory activity of recombinant MCoTI-II was 
measured by using a standard fluorescence assay (Figure 3c) [28]. The calculated Ki for porcine 
pancreatic trypsin was 25 pM, which is similar to the value reported in the literature for the 
natural product [28]. Recombinant MCoTI-II was also characterized by homonuclaer 2D-NMR. 
Deviations in the chemical shifts for the HaC and HaN protons for the recombinant and natural 
cyclotide [26, 27] were uniformly less than 0.05 ppm  (Figure 3d), confirming the native structure 
of recombinant MCoTI-II.
In summary, we have described for the first time the biosysthesis of a fully functional cyclotide 
inside living bacterial cells. This was accomplished by using an intein-mediated cyclization 
approach. The cyclized product folds spontaneously inside the bacterial cytoplasm to give the 
fully functional cyclotide. The use of engineered E. coli cell lines that promote disulfide bridge 
formation clearly improved the yield of MCoTI-II formation. Under these conditions, it was 
possible to reach intracellular concentrations up to 5 µM in folded cyclotide. These results open 
the possibility for the creation of cyclotide-based libraries that could be screened for their ability 
to attenuate or inhibit molecular processes inside living cells [31, 32].
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Figures and Schemes
Scheme 1. Sequences of the different precursors used in this work for the in vivo production of 
MCoTI-II. The sequence corresponding to loop 1, which is responsible for binding to the active 
site of trypsin, is in green as a reference.
Figure 1. Primary and tertiary structure of cyclotides from the plants Momordica 
cochinchinensis (MCoTI-II) and Oldenlandia affinis (Kalata B1).
Figure 2. Biosynthetic approach for the in vivo production of cyclotide MCoTI-II inside live E. 
coli cells. Backbone cyclization of the linear cyclotide precursor is mediated by a modified 
protein splicing unit or intein. The cyclized product then folds spontaneously in the bacterial 
cyctoplasm.
Figure 3. a) SDS PAGE analysis of the expression levels and in vivo cleavage of precursor 
proteins 1 and 2. b) Analytical reverse-phase HPLC trace of soluble cellular fraction from 
construct 1 after being purified on trypsin-immobilized agarose beads. The asterisk denotes the 
fully folded McoTI-II. Inset, ES-MS analysis of affinity purified MCoTI-II. c) Inhibition of 
porcine trypsin by recombinant MCoTI-II. d) Summary of the 1H-NMR assignments for the 
backbone protons: ∆d(1H) are the deviations in the chemical shifts of the main chain protons 
between the recombinant and the natural MCoTI-II cyclotide [26, 27]. 
